Videos

Distinguishing agitation from depression, anxiety, and psychosis shapes everything that follows in treatment. The panel walks through the clinical differences and where formal screening scales genuinely fit into daily practice.

Agitation eventually affects nearly every patient with Alzheimer's disease, yet it rarely looks like simple aggression. The panel outlines how common it is, the many forms it takes, and why it so often goes unrecognized.

Clinicians learn how to assess and treat sexual dysfunction in depression, menopause, and psych meds—plus drug options that preserve desire and arousal.

How psilocybin, LSD, and mescaline hit 5‑HT2A—and why downstream signaling, not binding alone, may shape future psychedelic care.

Learn how gene variants shape CYP450 metabolism, receptors, and transporters—explaining intermediate phenotypes that influence psychiatric medication response.

HLP003 shows rapid, durable MADRS improvement in adjunctive MDD phase 2; phase 3 tests intermittent dosing to cut daily pill burden.

Amae Health links wearables, AI, and biomarkers to cut rehospitalizations—now racing to prove relapse prevention gains and unlock reimbursement.

Nardin Valentin, DO, debunks common hormone therapy myths and makes the case for HRT as standard in perimenopausal and menopausal psychiatric care.

Amae Health's chief medical officer argues mental health lacks the outcome measures primary care already uses, and that wearable biomarkers could fill that gap.

Why benzodiazepines still anchor acute anxiety care: when short-term use fits, how to spot red flags, and taper safely.

Miller urges psychiatry to look beyond DSM labels, weighing biological, psychological, social, cultural and spiritual factors to personalize care.

Amae Health's chief medical officer discusses why Fitbit, Oura, and Apple Watch data diverge, and how AI foundation models could soon make any wearable clinically useful.

Amae Health's chief medical officer says its treated patients see 30-day rehospitalization rates of 2% to 3%, vs 20% to 25% typically, though biomarkers' exact role remains unproven.

Nardin Valetin, DO, explains how to spot hormonally driven mood symptoms in perimenopause and when HRT can support psychiatric treatment.

GWAS supports psychiatry’s labels, but symptoms vary; speech biomarkers help pinpoint drivers and guide treatment across depression, OCD, schizophrenia.

Clinicians unpack integrated behavioral health: collaborative care, cross-training, and workforce gaps shaping better outcomes for severe mental illness.

Curiosity-based habit training helps stop worry and the itch-scratch loop in atopic dermatitis, easing stress triggers and flares.

Learn how community-based supports, clinician self-reflection, and culturally responsive systems close mental health gaps beyond the clinic.

UBP EEG system turns quick clinic recordings into scalable brain biomarkers to guide depression treatment and advance objective psychiatry care.

Discover why skin and mental health care align: managing steroid psychiatric effects, using TMS, and prioritizing CBT for sleep, pain, and anxiety.

Explore how anxiety, stigma, and medications shape skin disease—psychodermatology urges integrated dermatology-psychiatry care for better outcomes.

Why care improves when clinicians ask about housing, work, money and access—using culturally responsive tools to uncover hidden stressors.

A new system for dry EEG measurement expands imaging options for psychiatry.

Learn how psychiatrists ask about identity with curiosity, transparency, and cultural humility—building trust, reducing assumptions, and shaping culturally informed treatment plans.

Learn more about ADHD across populations in this podcast episode.

Explore why combining medication and psychotherapy often improves major depression outcomes, plus the latest debates on treatment sequencing and public trust in psychiatry.

Psychiatrists admit carrying benzos for travel sleep or anxiety; learn why experts say occasional use differs from dependence and withdrawal risk.

HLP003, a deuterated psilocin agonist, enters phase 3 as an add-on for MDD, aiming to boost SSRI/SNRI response earlier.

From tricyclics to esketamine, Ron Pies, MD, explains antidepressant progress and why precise diagnosis matters when treating today’s diverse depression.

Psychiatrists rebut antidepressant myths, outlining modest benefits, real but manageable risks, and why slow tapering matters for withdrawal.